Search

Displaying results 821 - 830 of 5383 in total
  1. Drug

    Pergolide

    go.drugbank.com/drugs/DB01186
    ApprovedVet approvedWithdrawn

    The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. … While the use of pergolide in humans is still approved in only some countries, pergolide is mainly used for veterinary purposes.

  2. Drug

    Selenium

    go.drugbank.com/drugs/DB11135
    ApprovedInvestigationalVet approved

    Selenium is a trace metal in the human body particularly important as a component of glutathione peroxidase, an important enzyme in the prevention of cellular damage by free radicals and reactive oxygen

  3. Drug

    Ganaxolone

    go.drugbank.com/drugs/DB05087
    ApprovedInvestigational

    [L41130] It was approved under the brand name ZTALMY by the US FDA in March 2022 for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), becoming the first FDA-approved treatment … [L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636]

  4. Drug

    Citatuzumab Bogatox

    go.drugbank.com/drugs/DB06072
    Investigational

    VB6-845 is a humanized antibody fragment targeting EpCAM fused with the deimmunized form of the cytotoxin Bouganin and is designed for systemic use against metastatic cancer.

  5. Drug

    Sulfamethoxazole

    go.drugbank.com/drugs/DB01015
    ApprovedInvestigational

    Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with trimethoprim, which inhibits a sequential step in bacterial folic ac...

    Mixtures: Sulfamethoxazole and Trimethoprim for Injection, USP, Sulfamethoxazole and Trimethoprim for Injection, USPCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Gadoteridol

    go.drugbank.com/drugs/DB00597
    ApprovedInvestigational

    [A263076] Initially approved by the FDA in 1992, gadoteridol received additional approval in 2020 for use in pediatric patients less than 2 years old.[L49876] … [A263076,A263081,L49871] It was 1 of the 3 macrocyclic gadolinium-based contrast agents (GBCAs) that was mandated by the EMA to replace linear gadolinium-based contrast agents due to concerns about retained

  7. Drug

    Acipimox

    go.drugbank.com/drugs/DB09055
    ApprovedInvestigational

    Long-term administration is associated with reduced mortality, but unwanted effects limit its clinical use. … Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL.

  8. Drug

    Hydroxyproline

    go.drugbank.com/drugs/DB08847
    Approved

    Therapeutically, hydroxyproline is being studied as an an experimental medicine but is approved in France as a combination topical gel product called Cicactive for small, superficial wounds.

    Mixtures: Isa Knox Smart Bb Sun, Isa Knox Ageless Serum Makeup Base 10Products: Isa Knox Wrinkle Decline Double Effect Rf3 Wrinkle, Isa Knox Wrinkle Decline Double Effect Rf3 Wrinkle Eye Filler
  9. Drug

    Peppermint oil

    go.drugbank.com/drugs/DB11198
    ApprovedInvestigational

    this use is unclear. … Due to its effectiveness in relaxing GI smooth muscle but ability to induce gastroesophageal reflux, enteric-coated formulations of peppermint oil has been established which bypass the upper GI tract unmetabolized

  10. Drug

    Flosequinan

    go.drugbank.com/drugs/DB13228
    ApprovedWithdrawn

    Flosequinan was approved in the USA and the UK for a year prior to being withdrawn from the market due to increased mortality in chronic heart failure patients, found in drug trials.[A174979,L43942]